BVS 857

Drug Profile

BVS 857

Alternative Names: BVS-857

Latest Information Update: 02 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihyperglycaemics; Growth factors
  • Mechanism of Action Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Burns; Spinal muscular atrophy
  • No development reported Insulin resistance

Most Recent Events

  • 22 Apr 2017 Efficacy and adverse event data from a phase II trial presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Insulin-resistance in USA (Parenteral)
  • 01 Apr 2016 Novartis completes a phase II trial in Spinal muscular atrophy in USA, Denmark, Germany, Italy (SC, IV) (NCT02024932)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top